Table 2.
Comparison of Conventional and Advanced Imaging Volumes by Treatment Type (in Cubic Centimeters)
| Dose-Escalation Trial: Baseline | Non-Trial: Baseline | P Value | Dose-Escalation Trial: Mid-RT | Non-Trial: Mid-RT | P Value | Dose-Escalation Trial: Absolute Change | Non-Trial: Absolute Change | P Value | Dose-Escalation Trial: % Change | Non-Trial: % Change | P Value | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Count | ||||||||||||
| N | 26 | 23 | 26 | 23 | 26 | 23 | 26 | 23 | ||||
| Enhancing tumor (TVGd) | ||||||||||||
| Median (IQR) | 16.8 (10.1, 30.6) | 24.2 (17.5, 39.8) | .08 | 9.9 (5.2, 18.6) | 26.0 (15.7, 37.3) | <.01 | −5.8 (−10.5, −2.4) | −1.6 (−6.0, 3.9) | .13 | −39.9 (−56.2, −25.1) | −16.0 (−25.9, 17.0) | .01 |
| FLAIR volume (TVFLAIR) | ||||||||||||
| Median (IQR) | 71.4 (40.3, 118.2) | 67.8 (43.4, 96.7) | 0.01 | 43.9 (26.6, 79.3) | 58.2 (40.8, 95.3) | .34 | −22.7 (−52.1, −3.1) | −3.2 (−13.5, 2.3) | .41 | −33.3 (−47.3, −22.7) | −3.7 (−24.7, 3.7) | .02 |
| Hypercellular tumor (TVHCV) | ||||||||||||
| Median (IQR) | 5.9 (3.2, 10.8) | 7.6 (4.4, 11.4) | <.01 | 1.7 (0.7, 3.6) | 7.9 (1.7, 12.0) | .04 | −3.6 (−5.9, −1.6) | 0.3 (−3.3, 2.7) | .19 | −70.8 (−90.4, −33.9) | 4.9 (−30.2, 23.1) | <.01 |
| Hyperperfused tumor (TVCBV) | ||||||||||||
| Median (IQR) | 4.3 (1.8, 9.3) | 5.7 (2.2, 17.2) | .53 | 4.1 (1.1, 8.9) | 7.7 (0.9, 19.1) | .05 | −0.4 (−1.1, 1.0) | −0.1 (−1.8, 0.7) | .17 | −8.9 (−70.6, 18.5) | −2.5 (−23.2, 17.0) | .60 |
| Combined TVHCV/TVCBV | ||||||||||||
| Median (IQR) | 9.0 (6.1, 18.6) | 12.6 (8.0, 26.1) | .02 | 5.7 (2.3, 13.4) | 12.0 (6.1, 28.7) | .03 | −2.9 (−5.3, −1.8) | −0.5 (−3.1, 1.3) | .15 | −40.6 (−74.5, −16.9) | −6.1 (−21.6, 6.4) | <.01 |
Abbreviations: FLAIR, fluid-attenuated inversion recovery; IQR, interquartile range; RT, radiation therapy.